Positive: Legend Biotech reports strong financial results and positive efficacy data for CARVYKTI®

From GlobeNewswire: 2024-08-09 07:00:00

Legend Biotech’s CARVYKTI® net trade sales hit approximately $186 million, with positive overall survival results in the CARTITUDE-4 study. The company has cash equivalents and short-term investments totaling $1.3 billion, ensuring financial stability until 2026. Regulatory approvals in the UK and Canada highlight the drug’s efficacy in treating multiple myeloma. Key updates also include positive interim results and milestone payments. Legend Biotech aims to expand manufacturing capacity to meet growing demand for CARVYKTI®.



Read more at GlobeNewswire:: Legend Biotech Reports Second Quarter 2024 Results and